Literature DB >> 16415907

Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor.

Pui Man Hoi1, C Robin Hiley.   

Abstract

Oleamide (cis-9-octadecenoamide) exhibits some cannabimimetic responses despite its low affinities at the currently known cannabinoid receptors. Here we have investigated whether or not it is a vasorelaxant in rat small mesenteric arteries. Oleamide elicited vasorelaxation (EC50=1.2+/-0.2 microM, Rmax=99.1+/-3.9%, n=8) which was reduced by endothelial removal. Nitric oxide synthase inhibition reduced the response (EC50=5.3+/-1.6 microM, Rmax=59.2+/-7.7%, n=7; P<0.01) as did blockade of Ca2+-sensitive K+ channels (KCa) with apamin plus charybdotoxin (both 50 nM) (EC50=2.1+/-0.2 microM, Rmax=58.4+/-1.9%, n=5; P<0.05). Desensitisation of vanilloid receptors with capsaicin (10 microM for 30 min) shifted the oleamide concentration-response curve approximately 30-fold to the right (n=7; P<0.01). Pertussis toxin (400 ng ml-1 for 2 h) caused a two-fold shift in the response curve (EC50=2.2+/-0.4 microM, Rmax=66.8+/-4.5%, n=6; P<0.01). Rimonabant (CB1 cannabinoid receptor antagonist; SR141716A; 3 microM) significantly inhibited relaxation induced by oleamide (EC50=3.5+/-0.3 microM, Rmax=75.1+/-1.9%; n=8; P<0.05). In contrast, neither the more selective CB1 receptor antagonist, AM251 (1 microM), nor the CB2 antagonist, SR144528 (1 microM), had significant effects. O-1918 (10 microM), a putative antagonist at a novel endothelial cannabinoid receptor (abnormal-cannabidiol site), markedly reduced the relaxation to oleamide (n=7; P<0.01). It is concluded that oleamide responses in the rat isolated small mesenteric artery are partly dependent on the presence of the endothelium, activation of Ca2+-sensitive K+ channels (KC)) and involve capsaicin-sensitive sensory nerves. Oleamide may share a receptor (sensitive to rimonabant and O-1918, and coupled to KC) and Gi/o) with anandamide in this vessel. This might be distinct from both of the known cannabinoid receptors and the novel abnormal-cannabidiol site.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415907      PMCID: PMC1616976          DOI: 10.1038/sj.bjp.0706643

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor.

Authors:  S Kagota; Y Yamaguchi; K Nakamura; T Sugiura; K Waku; M Kunitomo
Journal:  Eur J Pharmacol       Date:  2001-03       Impact factor: 4.432

2.  In silico patent searching reveals a new cannabinoid receptor.

Authors:  David Baker; Gareth Pryce; Wayne L Davies; C Robin Hiley
Journal:  Trends Pharmacol Sci       Date:  2005-11-28       Impact factor: 14.819

3.  Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats.

Authors:  S Huitrón-Reséndiz; L Gombart; B F Cravatt; S J Henriksen
Journal:  Exp Neurol       Date:  2001-11       Impact factor: 5.330

4.  Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

Authors:  Z Járai; J A Wagner; K Varga; K D Lake; D R Compton; B R Martin; A M Zimmer; T I Bonner; N E Buckley; E Mezey; R K Razdan; A Zimmer; G Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

5.  Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent.

Authors:  Somnath Mukhopadhyay; Barry M Chapnick; Allyn C Howlett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06       Impact factor: 4.733

6.  N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.

Authors:  T Bisogno; D Melck; N M Gretskaya; V V Bezuglov; L De Petrocellis; V Di Marzo
Journal:  Biochem J       Date:  2000-11-01       Impact factor: 3.857

7.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.

Authors:  Amy C Porter; John-Michael Sauer; Michael D Knierman; Gerald W Becker; Michael J Berna; Jingqi Bao; George G Nomikos; Petra Carter; Frank P Bymaster; Andrea Baker Leese; Christian C Felder
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

8.  Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.

Authors:  R White; W S Ho; F E Bottrill; W R Ford; C R Hiley
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 9.  Cardiovascular effects of cannabinoids.

Authors:  Michael D Randall; David Harris; David A Kendall; Vera Ralevic
Journal:  Pharmacol Ther       Date:  2002-08       Impact factor: 12.310

10.  Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.

Authors:  Aron H Lichtman; E Gregory Hawkins; Graeme Griffin; Benjamin F Cravatt
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

View more
  18 in total

1.  Effects of Oleamide on the Vasomotor Responses in the Rat.

Authors:  Carlos Hernández-Díaz; Marco Antonio Juárez-Oropeza; Dieter Mascher; Natalia Pavón; Ignacio Regla; María Cristina Paredes-Carbajal
Journal:  Cannabis Cannabinoid Res       Date:  2020-02-27

Review 2.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

3.  Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression.

Authors:  Markus Waldeck-Weiermair; Cristina Zoratti; Wolfgang F Graier; Karin Osibow; Nariman Balenga; Edith Goessnitzer; Maria Waldhoer; Roland Malli
Journal:  J Cell Sci       Date:  2008-04-29       Impact factor: 5.285

Review 4.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 5.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

6.  Primary fatty acid amide metabolism: conversion of fatty acids and an ethanolamine in N18TG2 and SCP cells.

Authors:  Emma K Farrell; Yuden Chen; Muna Barazanji; Kristen A Jeffries; Felipe Cameroamortegui; David J Merkler
Journal:  J Lipid Res       Date:  2011-11-16       Impact factor: 5.922

7.  Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

Authors:  P M Hoi; C Visintin; M Okuyama; S M Gardiner; S S Kaup; T Bennett; D Baker; D L Selwood; C R Hiley
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

8.  Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries.

Authors:  Varadarajan Sudhahar; Sean Shaw; John D Imig
Journal:  Eur J Pharmacol       Date:  2009-04-01       Impact factor: 4.432

Review 9.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

Review 10.  The therapeutic potential of novel cannabinoid receptors.

Authors:  Faith R Kreitzer; Nephi Stella
Journal:  Pharmacol Ther       Date:  2009-02-25       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.